$DXCM

Biotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.

DexCom (DXCM) designs continuous glucose monitoring systems. The stock lagged the S&P 500 and XLV over 52 weeks but gained 37.2% YTD. After Q2 2026 results on Jul. 30, adjusted EPS was $0.70 and revenue $1.31B, up 13% YoY, beating estimates. DexCom raised 2026 revenue guidance to $5.18B-$5.25B. Canaccord lifted its price target to $90; mean target $92.48.

DexCom (DXCM) shares are up 34.8% YTD in 2026 after a 14.7% drop in 2025, outperforming the industry and the S&P 500. In Q2, revenue rose 13% YoY and organic growth was 12%. U.S. revenue grew 11% and international 19%. Drivers cited include CGM expansion in non-insulin Type 2 diabetes and G7 15 Day adoption, which improved gross margin by about 400 bps.

DexCom (DXCM) shares rose 52.5% over three months, outpacing the Zacks medical sector and the S&P 500, according to Zacks. In Q2 2026, revenue grew 13.1% to $1.31B and adjusted EPS was 70 cents. Adjusted gross margin rose to 64.1% and operating margin to 25.1%. The stock trades at 30.7x forward earnings versus peers, with competition and litigation risks noted.

DexCom (DXCM) raised its 2026 outlook after a stronger Q2. Q2 revenue was $1.31B (+13.1% YoY) with adjusted EPS of $0.70 and adjusted operating margin of 25.1%. For 2026, management now expects revenue of $5.18-$5.25B, adjusted gross margin ~64%, operating margin 23.5%-24%, and EBITDA margin 31.5%-32%, citing G7 15-day rollout. FX and transition costs remain risks.

DexCom reported Q2 2026 sales of $1,308.4 million and net income of $249.1 million, both higher than the prior year, and raised full-year 2026 revenue guidance to $5.18 billion to $5.25 billion, according to the company. The article says the update may affect the investment case amid risks like CMS pricing pressure and execution.

Amazon shares rose after Q2 results, with revenue up 20% Y/Y to $200.6B and AWS revenue up 36.7% to $42.2B. Dexcom hit a 52-week high after Q2 results and a 2026 revenue outlook of $5.18B to $5.25B. Corteva fell after Q2 revenue of $6.38B, but raised guidance, with operating EBITDA above $4.3B. Coinbase dropped after Q2 GAAP EPS of -$1.36 and weaker Q3 subscription and services revenue.

DexCom (DXCM) reported Q2 2026 results with higher sales and earnings and raised full-year revenue guidance to about $5.18b to $5.25b. The stock has risen sharply recently. Simply Wall St discusses valuation versus a $91.64 fair value estimate and notes reimbursement expansion and CGM coverage, alongside risks from Medicare pricing pressure and competition.

U.S. S&P 500 and Nasdaq 100 E-mini futures rose as WTI crude fell more than 6% after President Trump called off a strike on Iran and said talks would start Monday. Treasuries rose, with the 10-year yield down to 4.69%. The article cites recent stock moves in AMZN, DXCM, MPWR, and AAPL, and outlines upcoming earnings, Fed speakers, and U.S. jobs data.

DexCom (DXCM) reported Q2 2026 revenue of $1.31B, up 13% reported and 12% organic year over year. Non-GAAP gross margin was 64.1%, non-GAAP operating income $328.3M, and non-GAAP EPS $0.70. Free cash flow was $600M in H1. FY2026 revenue guidance raised to $5.18B-$5.25B. The company completed the Nutrisense acquisition and discussed CONNECT trial and G7 15-day progress.